Longeveron Wins $3.8M NIH SBIR Grant toward Stem Cell Aging Frailty Research

Adult stem cell therapy developer Longeveron has won a $3.8 million NIH Small Business Innovation Research (SBIR) grant for its research toward developing stem cell therapies for aging frailty.Longeveron said it would apply the grant to the clinical research of its Mesenchymal Stem Cells (MSCs) as treatment for aging frailty, a geriatric syndrome of multisystem physiological decline distinct from normal aging that heightens vulnerability to adverse and serious health conditions in older people.L